.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,389,653

« Back to Dashboard

Details for Patent: 5,389,653

Title: Catechol derivatives
Abstract:Catechol derivatives of the formula ##STR1## wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adenosylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuronal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure. Formula Ia above embraces not only compounds which form part of the invention, but also known compounds; the compounds which form part of the invention can be prepared according to known methods.
Inventor(s): Bernauer; Karl (Oberwil, CH), Borgulya; Janos (Basel, CH), Bruderer; Hans (Biel-Benken, CH), Da Prada; Mose (Riehen, CH), Zurcher; Gerhard (Basel, CH)
Assignee: Hoffman-La Roche Inc. (Nutley, NJ)
Filing Date:Apr 16, 1993
Application Number:08/048,685
Claims:1. A compound of the formula: ##STR24## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.11 wherein R.sup.11 is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hetero ring members,

or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof.

2. A compound, according to claim 1, wherein Rb is situated in the p-position to Ra.

3. A compound, according to claim 2, wherein Ra is nitro.

4. A compound, according to claim 3, wherein Rb is hydrogen, chlorine or fluorine.

5. A compound, according to claim 4, wherein Rb is hydrogen.

6. A compound, according to claim 5, wherein Rc' is the group -CO-R.sup.11 and R.sup.11 is an aromatic, mononuclear heterocyclic group with 1-3 nitrogen atoms as the hetero ring member(s) which is attached via a carbon atom.

7. A compound, according to Claim 6, wherein R.sup.11 is a pyridyl group.

8. A compound, according to claim 1, 3,4-Dihydroxy-5-nitrophenyl 4-pyridyl ketone.

9. A compound according to claim 1, 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.

10. A pharmaceutical composition comprising a compound of the formula: ##STR25## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.1 wherein R.sup.1 is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hetero ring members,

or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.

11. A pharmaceutical composition, according to claim 10, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 4-pyridyl ketone.

12. A pharmaceutical composition according to claim 10, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.

13. A pharmaceutical composition comprising L-dopa, peripheral decarboxylase inhibitor, a compound of the formula: ##STR26## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.1 wherein R.sup.1 is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hereto ring members,

or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.

14. A pharmaceutical composition according to claim 10, wherein R.sup.1 is pyridyl.

15. A pharmaceutical composition according to claim 14, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.

16. A pharmaceutical composition for treating depression comprising an effective amount of a compound of the formula: ##STR27## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.1 wherein R.sup.l is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hereto ring members,

or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.

17. A pharmaceutical composition according to claim 16, wherein R.sup.1 is pyridyl.

18. A pharmaceutical composition according to claim 17, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.

19. A pharmaceutical composition for treating Parkinson's disease comprising L-dopa, a peripheral decarboxylase inhibitor, a compound of the formula: ##STR28## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.1 wherein R.sup.1 is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hereto ring members,

or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.

20. A pharmaceutical composition according to claim 19, wherein R.sup.1 is pyridyl.

21. A pharmaceutical composition according to claim 20, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.

22. A pharmaceutical composition for inhibiting catechol-O-methyl-transferase, said composition comprising a catechol-O-methyl transferase inhibiting amount of a compound of the formula: ##STR29## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.1 wherein R.sup.1 is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hereto ring members,

or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.

23. A pharmaceutical composition according to claim 22, wherein R.sup.1 is pyridyl.

24. A pharmaceutical composition according to claim 23, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc